Theratechnologies Announces New Positive Results for two Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Ovarian Cancer - Seite 2

Commercially available anticancer drugs, like docetaxel, doxorubicin or tyrosine kinase inhibitors are linked to our investigational novel peptide to specifically target the Sortilin1 receptor. This could potentially improve the efficacy and safety of those agents.

Theratechnologies intends to initiate, by the end of 2020, a first-in-human clinical trial with TH1902 in cancer patients.

About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a commercial-stage biopharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical conditions, including those living with HIV. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR at www.sedar.com and on EDGAR at www.sec.gov

Forward-Looking Information
This press release contains forward-looking statements and forward-looking information, or, collectively, forward-looking statements, within the meaning of applicable securities laws, that are based on our management’s beliefs and assumptions and on information currently available to our management. You can identify forward-looking statements by terms such as "may", "will", "should", "could", “would”, "outlook", "believe", "plan", "envisage", "anticipate", "expect" and "estimate", or the negatives of these terms, or variations of them. The forward-looking statements contained in this press release include, but are not limited to, statements regarding the effects, safety and efficacy of Theratechnologies’ peptide-conjugates derived from its oncology platform on the potential treatment of various types of cancer and timelines to initiate a first-in-human clinical trial with TH1902 in cancer patients .

Forward-looking statements are based upon a number of assumptions and include, but are not limited to, the following: TH-1902 will be as effective and safe in humans as in mice and in vitro and in vivo results obtained thus far will be replicated into humans leading us to pursue the development of this peptide-conjugate and no event will occur resulting in a delay in initiating a clinical trial by the end of 2020.

Forward-looking statements are subject to a variety of risks and uncertainties, many of which are beyond our control that could cause our actual results to differ materially from those that are disclosed in or implied by the forward-looking statements contained in this press release. These risks and uncertainties include, among others, the risk that results (whether safety or efficacy, or both) obtained through the administration of TH-1902 into humans are different than into mice; difficulty in recruiting patients to begin a phase I clinical trial; further results using TH-1902 may not replicate in vivo results leading us to delay or to stop the pursuit of additional studies; and discovery or introduction of new treatments on the market for the treatment of cancer that we intend to develop our conjugate-peptides for could prove safer and more effective than  TH-1902 or TH-1904.